Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
about
The epigenetic landscape of acute myeloid leukemiaC/EBPα Dysregulation in AML and ALLGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaPost-remission therapy for acute myeloid leukemiaThe prognostic and functional role of microRNAs in acute myeloid leukemiaASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study GroupCEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a Chinese populationCEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.Targeting CD157 in AML using a novel, Fc-engineered antibody construct.Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.Molecular therapy for acute myeloid leukaemia.Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia - preliminary reportLong-term follow-up of cytogenetically normal CEBPA-mutated AMLThe NPM1 mutation type has no impact on survival in cytogenetically normal AML.C/EBPα and MYB regulate FLT3 expression in AMLDouble CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutationsCharacterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expressionStrategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technologyCCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinomaGene expression profiles associated with pediatric relapsed AML.Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemiaSomatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemiaEpigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells.Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF).An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis.Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic LeukemiaLenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemiaThe lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocolPotential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLAcute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia
P2860
Q21284742-E3907544-9750-4620-AA1E-F2870053FBCEQ22065117-D3CE3CA4-1FBE-458B-8390-A4F79DAB28D7Q26796514-467D2985-709E-450E-8204-F23275C62A4CQ26995867-1AD0E167-70D8-499E-8E27-2F784B32C8AEQ27693865-B4BAB71B-122D-4939-9F37-A4DDD93083BDQ27851679-B41E8917-7AD6-46DD-822A-CB6228AB729BQ27853039-52AA81DD-4349-43EE-A609-E4110EFB6D18Q31111079-42714342-2889-4E22-844D-40562A7BA0EFQ33573806-FDD73A8E-FC58-4EF0-892C-EB17C6AB2648Q33829283-DEA7CB08-7796-473D-A05D-DF9DCE0B80E7Q33873844-860DBCB4-D3F9-4D98-B86B-6945416144B5Q33925672-0ABABC7F-1B18-4077-A991-FFCA3AC8C02FQ34226754-CDD68317-6E1C-45CC-96BC-4C94EE5AA1C0Q34233639-9BAFD6FF-778A-4949-80A3-44CA94D5CEC7Q34315531-1A1C96AE-C59F-4FE4-B165-7C92616E7BAAQ34425939-987E3AD4-AA57-47C8-8CB2-8F82250F14D0Q34502042-2770CCD0-0064-4B55-8E58-EA83D95615F4Q34502869-A74786F2-D01D-40EC-B63B-35EFBE0AE5D6Q34541735-C215E56F-D88D-42AA-A1D7-CB9BBC5A96D5Q34612599-5D0AB1D8-16D2-4A6A-91BA-C9BF5D8219DEQ34635511-9B4D9776-42CA-43CC-BE62-0BF30DD23D59Q34649120-E2A095CD-EECC-4331-96CC-39C0C7B2D44DQ35083685-6411D3B5-639E-4AA7-8AD9-25DF2CE63008Q35194416-977CD675-0CF2-469E-9BF1-11CF5D249387Q35302035-89AADFF9-81FB-4649-8B34-173C59EF7B73Q35562821-A6819645-7585-4D45-9FA9-0C94268768CBQ35585976-AB9A1CD8-351A-4B79-A949-17C2572972BBQ35685082-DD44E0BD-4AA5-4E18-8E49-B3C82C313C74Q35788613-A0EC3FF5-7144-48D7-B20F-1AA5467B2F5EQ35900361-9FC3040E-A778-45E9-BA7D-26FD053968D6Q36125618-C553AACE-B554-4D93-969C-9083DA2B5187Q36250104-D26F4F18-1DE4-4BC1-8DCF-170A68FB1583Q36322508-FA56991D-DD35-46DA-8759-6D4360527E7DQ36512601-4F780402-7A93-480E-AB11-26BC40353C45Q36544646-DABFE1F8-479C-407F-B156-56BA86398B05Q36678141-8E59E0AC-710A-47D1-96B3-AE479E67AF20Q36715925-27D1A4ED-9F7C-4C7B-ADA3-80F8FB1BED26Q36797201-C36C1C39-A82B-40F8-823B-5C13B7FDB44AQ36849666-9BBCE61C-2E68-4848-9098-07EBC7AFD384Q36866323-04F0759E-B9DC-4027-A761-F2817541041F
P2860
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Acute myeloid leukemia with bi ...... a favorable clinical outcome.
@en
type
label
Acute myeloid leukemia with bi ...... a favorable clinical outcome.
@en
prefLabel
Acute myeloid leukemia with bi ...... a favorable clinical outcome.
@en
P2093
P50
P356
P1476
Acute myeloid leukemia with bi ...... a favorable clinical outcome.
@en
P2093
Annika Dufour
Bernhard Wörmann
Evelyn Zellmeier
Friederike Schneider
Jan Braess
Karsten Spiekermann
Maria-Cristina Sauerland
Stephanie Schneider
Thomas Büchner
Tobias Benthaus
P304
P356
10.1200/JCO.2008.21.6010
P407
P577
2009-12-28T00:00:00Z